Partnership8 May 2025, 08:32 pm
Remedium Lifecare's Subsidiary Announces Partnership with JiyaYu Lifesciences to Replace Animal-Origin Inputs in APIs
AI Summary
Remlife Global PTE LTD., a Singapore-based subsidiary of BSE-listed Remedium Lifecare Ltd. (India), has announced a strategic partnership with JiyaYu Lifesciences PTE Ltd., a green chemistry technology platform company. This collaboration aims to replace animal-origin raw materials in the manufacturing of active pharmaceutical ingredients (APIs) and advanced intermediates through proprietary fermentation and biocatalyst-based alternatives. JiyaYu will license out fully developed and scalable technologies to Remlife Global on an exclusive basis, which will be scaled up and commercialised at GMP-compliant contract manufacturing sites across multiple global jurisdictions.
Key Highlights
- Remlife Global and JiyaYu Lifesciences partner to replace animal-origin inputs in APIs with green chemistry solutions.
- JiyaYu will license out fully developed and scalable technologies to Remlife Global on an exclusive basis.
- Remlife Global will scale up and commercialise these technologies at GMP-compliant contract manufacturing sites across multiple global jurisdictions.
- Each technology has a minimum commercial potential of ¥50 crore per product, with EBITDA margins estimated between 20% to 25%.
- The partnership is a step towards building a more ethical, resilient, and sustainable pharmaceutical supply chain.